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Background
The long-term effects of sibutramine treatment on the rates of cardiovascular events 
and cardiovascular death among subjects at high cardiovascular risk have not been 
established.
Methods
We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, 
with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess 
the cardiovascular consequences of weight management with and without sibutra-
mine in subjects at high risk for cardiovascular events. All the subjects received 
sibutramine in addition to participating in a weight-management program during 
a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random 
assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo 
(4898 subjects). The primary end point was the time from randomization to the 
first occurrence of a primary outcome event (nonfatal myocardial infarction, non-
fatal stroke, resuscitation after cardiac arrest, or cardiovascular death).
Results
The mean duration of treatment was 3.4 years. The mean weight loss during the 
lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group 
achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood 
pressure decreased in both groups, with greater reductions in the placebo group 
than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a 
primary outcome event was 11.4% in the sibutramine group as compared with 
10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 
1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 
4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, 
respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 
1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). 
The rates of cardiovascular death and death from any cause were not increased.
Conclusions
Subjects with preexisting cardiovascular conditions who were receiving long-term 
sibutramine treatment had an increased risk of nonfatal myocardial infarction and 
nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by 
Abbott; ClinicalTrials.gov number, NCT00234832.)
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Obesity and excess weight are esca-lating public health concerns because they increase the prevalence of associat-
ed conditions such as diabetes mellitus and the 
risk of premature death.1,2 More than 80% of even 
highly motivated patients are unable to achieve 
weight loss with dietary and lifestyle modifica-
tions alone.3
Sibutramine is a norepinephrine and serotonin 
reuptake inhibitor that was approved for weight 
management in patients who are unable to lose 
weight by means of diet and exercise alone. 
Sibutramine induces satiety (resulting in reduced 
food intake) and an increase in energy expendi-
ture.4,5 In some patients, sibutramine increases 
blood pressure, pulse rate, or both, owing to its 
sympathomimetic effects.6 Sibutramine is not in-
dicated for patients with a history of cardiovascu-
lar disease; otherwise, treatment with sibutramine 
is recommended for no more than 1 to 2 years 
in patients who achieve a 5% weight loss. The 
Sibutramine Cardiovascular Outcomes (SCOUT) 
trial evaluated the long-term effects of sibutra-
mine treatment combined with diet and exercise 
on the rates of cardiovascular events and cardio-
vascular death among subjects who were at high 
cardiovascular risk.
Me thods
Study Design and Population
The SCOUT trial was a randomized, double-blind, 
placebo-controlled, multicenter trial that was con-
ducted from January 2003 through March 2009 
at 298 centers in 16 countries in Europe, Central 
America, South America, and Australia. The trial 
protocol has been described elsewhere.7,8
Eligible subjects included men and women, 
55 years of age or older, with a body-mass index 
(BMI; the weight in kilograms divided by the 
square of the height in meters) of at least 27 and 
no more than 45; subjects were also eligible if 
they had a BMI of at least 25 and less than 27 
and a waist circumference of at least 102 cm in 
the case of men or 88 cm in the case of women. 
Subjects were required to have a history of cardio-
vascular disease (defined as coronary artery dis-
ease, stroke, or peripheral arterial occlusive 
disease), type 2 diabetes mellitus with at least one 
other cardiovascular risk factor (hypertension, 
dyslipidemia, current smoking, or diabetic ne-
phrop athy), or both. Subjects who were enrolled in 
the study were categorized as belonging to one 
of three prespecified cardiovascular-risk groups: 
diabetes only (DM-only group), cardiovascular 
disease only (CV-only group), or both (CV–DM 
group). Exclusion criteria were symptoms of heart 
failure greater than New York Heart Association 
functional class II, blood pressure higher than 
160/100 mm Hg, a pulse rate of more than 100 
beats per minute, scheduled cardiac surgery or 
coronary angioplasty, or a weight loss of more 
than 3 kg within the previous 3 months.
All subjects underwent a 6-week lead-in period 
with single blinding (of the subjects), during 
which they received sibutramine at a dose of 
10 mg per day as well as advice regarding diet 
and exercise, so that subjects with early and per-
sistent increases in blood pressure or pulse rate 
could be identified and excluded from random-
ization. After this lead-in period, eligible subjects 
were randomly assigned, in a double-blind man-
ner, to receive sibutramine, at a dose of 10 mg 
per day, or placebo, in a 1:1 ratio; an increase in 
the dose of sibutramine to 15 mg per day was 
permitted according to the investigator’s judg-
ment, if weight loss was not sufficient. All sub-
jects participated in individualized cardioprotec-
tive diet and exercise programs that were designed 
to result in a reduction in calories of 600 kcal 
per day.9 Physicians were instructed to ensure that 
subjects received optimal management of medi-
cal conditions such as diabetes, hypertension, or 
dyslipidemia, according to national guidelines. 
Anthropometric measurements were obtained and 
vital signs assessed monthly for the first 3 months 
and every 3 months thereafter in the case of 
subjects taking a study drug and annually in the 
case of subjects who discontinued the study drug. 
Assessments to ascertain illness and death were 
performed in all patients every 3 months, and 
laboratory testing and electrocardiography were 
performed annually.
Subjects who continued in the study were fol-
lowed until the final visit, which occurred be-
tween November 2008 and March 2009; in the 
case of subjects who had discontinued the study 
drug, follow-up data were obtained until March 
2009. The duration of individual treatment was 
calculated as the time from randomization to 
the final visit.
Outcome Measures and Adverse Events
The primary outcome was the time from random-
ization to the first occurrence of a primary out-
come event. The primary outcome events were 
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nonfatal myocardial infarction, nonfatal stroke, 
resuscitation after cardiac arrest, and cardiovas-
cular death. Death from any cause was a second-
ary outcome. A full list of the secondary outcomes 
is provided in the Supplementary Appendix, 
available with the full text of this article at NEJM 
.org. Potential outcome events were evaluated by 
the event adjudication committee with the use of 
prespecified criteria.
Adverse events were reported if they were se-
rious or contributed to discontinuation of the 
study drug. Adverse events were coded according 
to the Medical Dictionary for Regulatory Activities, 
version 12.0, with the use of the medical terms 
provided by the investigators.
Study Oversight
The study was conducted in accordance with In-
ternational Conference on Harmonisation Good 
Clinical Practice guidelines. The study protocol 
was approved by the relevant ethics committee 
for each participating site. All subjects gave writ-
ten informed consent. The study was designed by 
the executive steering committee (see the Appen-
dix), in cooperation with the sponsor (Abbott 
Laboratories). Data were collected, managed, and 
analyzed by the sponsor, with the assistance of 
MDS Pharma Services and oversight by the exec-
utive steering committee. The study was moni-
tored by an independent data and safety monitor-
ing committee. The initial draft of the manuscript 
was written by the first author. All the authors 
contributed to subsequent drafts and had unre-
stricted access to the data during this process. 
All the authors made the decision to submit the 
manuscript for publication and assume responsi-
bility for the accuracy and completeness of the 
data. The protocol, including the statistical analy-
sis plan, is available at NEJM.org. All the authors 
attest that the study was performed in accordance 
with the protocol and the statistical analysis plan.
Statistical Analysis
We estimated that we would need to enroll 9000 
subjects (4500 in each group) and to continue the 
study until 2160 confirmed primary outcome 
events had occurred to have 80% power to detect 
an 11.4% reduction in the hazard ratio with 
sibutramine as compared with placebo, or vice 
versa, assuming a 7% annual event rate10-14 with 
placebo and a 30% rate of discontinuation of 
sibutramine, at a two-sided type I error rate of 
0.05. Owing to a low rate of primary outcome 
events, recruitment was restricted after 15 months 
to the highest cardiovascular-risk group (CV–DM), 
with the result that the CV–DM group represent-
ed 60% of the overall study population. In addi-
tion, recruitment was extended from 2 years to 
2.8 years, and study follow-up was extended from 
5 years to 6 years. It was agreed to stop the trial 
after 6 years, at which time 49% of the predicted 
primary outcome events had occurred. This rate 
allowed the detection of a 15.9% reduction in the 
hazard ratio with 80% power.
Prespecified time-to-event analyses of the rates 
of primary outcome events and of death from 
any cause in the intention-to-treat population 
were performed with the use of a Cox model, 
with factors for treatment, country, sex, and age 
(at the beginning of the lead-in period) as cova-
riates. Estimates of hazard ratios, 95% confidence 
intervals, and log-rank P values were calculated 
within the Cox model framework. Secondary 
analyses of interactions between treatment and 
cardiovascular-risk group were evaluated with the 
use of Cox models. A sensitivity analysis was con-
ducted that was restricted to the period during 
which the subjects were receiving the study drug.
Mean changes in body weight and vital signs 
from the baseline of the lead-in period to each 
scheduled study visit were evaluated longitudi-
nally with the use of a mixed-effects model for 
repeated measures,15 including factors for treat-
ment; country; sex; age; baseline values for body 
weight, systolic blood pressure, diastolic blood 
pressure, and pulse rate; visit; interaction be-
tween treatment and visit; and interaction be-
tween baseline values and visit. The following 
covariance structures were considered: unstruc-
tured, compound symmetric, first-order autore-
gressive, and Toeplitz. The covariance structure 
that provided the best fit according to Akaike’s 
information criterion was used in the analysis.
All statistical analyses were performed with 
the use of SAS software, version 9.1.3 (SAS Insti-
tute). All statistical tests were two-tailed. P values 
of less than 0.05 were considered to indicate 
statistical significance, unless otherwise speci-
fied. No statistical imputation was performed for 
missing data.
R esult s
Subjects
A total of 9804 of the 10,744 subjects (91.3%) 
completed the lead-in period, were randomly as-
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signed to a group, and were given a study drug; 
4906 subjects were given sibutramine, and 4898 
placebo (Fig. 1). The mean age of the subjects 
was 63.2 years (range, 51 to 88). At baseline, de-
mographic and other characteristics were gener-
ally similar between the sibutramine and placebo 
groups and among the cardiovascular-risk groups 
(Table 1).
The mean duration of study treatment after 
randomization was 3.4 years (interquartile range, 
2.1 to 4.7), during which 40.2% of the subjects in 
the sibutramine group and 42.3% of those in the 
placebo group permanently discontinued the 
study drug. A total of 41,408 person-years of 
data were accrued for primary outcome events 
(20,626 in the sibutramine group and 20,782 in 
the placebo group). At the end of the study, the 
status with respect to death was unknown in 95 
subjects (1.0%) and the status with respect to 
nonfatal primary outcome events was unknown 
in 397 subjects (4.0%).
Changes in Weight, Blood Pressure,  
and Pulse
During the 6-week lead-in period, when all the 
subjects received sibutramine, there was a mean 
weight loss of 2.6 kg in the cohort that subse-
quently underwent randomization. After random-
ization, there was a further reduction in weight 
in the sibutramine group (maximum mean ad-
ditional weight loss, 1.7 kg at 12 months) and a 
mean increase in weight in the placebo group 
(0.7 kg by month 12). Thereafter, both groups 
had a limited increase in mean weight (Fig. 2A). 
Similar mean weight-change profiles were ob-
served in analyses of the subjects according to 
cardiovascular-risk group.
There was a mean decrease in blood pressure 
during the lead-in period (reductions of 4.7 mm Hg 
systolic and 1.7 mm Hg diastolic). Mean blood 
pressure remained below initial values in both 
groups throughout the treatment period but was 
consistently higher in the sibutramine group than 
in the placebo group, with mean differences be-
tween the groups ranging from −0.3 to 1.2 mm Hg 
systolic and from 0.6 to 1.4 mm Hg diastolic. 
Pulse rate was also consistently higher in the 
sibutramine group than in the placebo group, 
with mean differences between the groups rang-
ing from 2.2 to 3.7 beats per minute (Fig. 2B, 
2C, and 2D). Similar changes and differences 
were observed in analyses of the subjects accord-
ing to cardiovascular-risk group.
Primary Outcome Events and Death  
from Any Cause
The risk of a primary outcome event was in-
creased by 16% in the sibutramine group as 
compared with the placebo group (hazard ratio, 
1.16; 95% confidence interval [CI], 1.03 to 1.31; 
P = 0.02), with overall incidences of 11.4% and 
10.0%, in the two groups, respectively (Fig. 3). 
The individual rates of nonfatal myocardial in-
farction and stroke, which were components of 
the primary outcome event, were also increased 
in the sibutramine group (hazard ratio for nonfa-
tal myocardial infarction, 1.28; 95% CI, 1.04 to 
1.57; P = 0.02; hazard ratio for nonfatal stroke, 
1.36; 95% CI, 1.04 to 1.77; P = 0.03). No signifi-
cant between-group difference was observed 
with respect to cardiovascular death (hazard ra-
tio, 0.99; 95% CI, 0.82 to 1.19; P = 0.90). Resusci-
tation after cardiac arrest occurred in 0.2% or 
less of the subjects in each group. No significant 
difference was observed between the study groups 
with respect to death from any cause (hazard ra-
tio with sibutramine, 1.04; 95% CI, 0.91 to 1.20; 
P = 0.54). A sensitivity analysis that was restricted 
to the period during which the subjects were re-
ceiving the study drug showed similar results 
with respect to primary outcome events (hazard 
ratio with sibutramine, 1.17; 95% CI, 1.02 to 1.35; 
P = 0.02).
In an analysis of the three cardiovascular-risk 
groups, the increases in nonfatal primary out-
come events were seen in the CV-only and CV–DM 
groups but not in the DM-only group (Fig. 3). 
The times to the primary outcome events and to 
death from any cause for the overall population 
are shown in Figure 4. Respective results ac-
cording to cardiovascular-risk group are provid-
ed in the Supplementary Appendix. Although the 
treatment–event profiles for the primary outcome 
differed among the three cardiovascular-risk 
groups, no significant interaction was seen be-
tween treatment and cardiovascular risk group 
(P = 0.58 for the interaction), but the analysis had 
limited statistical power, as evidenced by the wide 
confidence interval in the CV-only group (hazard 
ratio, 1.28; 95% CI, 0.92 to 1.78; P = 0.15) and the 
DM-only group (hazard ratio, 1.01; 95% CI, 0.74 
to 1.38; P = 0.95).
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9804 Were included in the intention-to-
treat population
9805 Underwent randomization
1 Was not dispensed study drug
9996 Completed lead-in
191 Completed lead-in but did not undergo
randomization
10,744 Took sibutramine during lead-in
748 Discontinued sibutramine
340 Had an adverse event or outcome event
199 Withdrew consent
13 Were lost to follow-up
125 Had protocol violation
22 Required treatment with contraindicated
medication
49 Had other reasons
10,777 Subjects enrolled in 6-wk lead-in
33 Did not take sibutramine
1 Had an adverse event or outcome event
20 Withdrew consent
3 Were lost to follow-up
3 Had protocol violation
2 Required treatment with contraindicated
medication
4 Had other reasons
1973 Discontinued sibutramine
633 Had an adverse event
or outcome event
47 Were lost to follow-up
64 Had protocol violation
110 Required treatment with
contraindicated medica-
tion
225 Had lack of efficacy
663 Withdrew consent
231 Had other reasons
2073 Discontinued placebo
581 Had an adverse event
or outcome event
58 Were lost to follow-up
71 Had protocol violation
140 Required treatment with
contraindicated medica-
tion
290 Had lack of efficacy
692 Withdrew consent
241 Had other reasons
 4906 Were assigned to receive
sibutramine
4898 Received sibutramine
8 Did not receive sibutramine
4898 Were assigned to receive placebo
4887 Received placebo
11 Did not receive placebo
2933 (59.8%) Completed treatment
period
2825 (57.7%) Completed treatment
period
Figure 1. Screening, Enrollment, Randomization, and Follow-up of Study Subjects.
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Adverse Events
Serious adverse events and adverse events leading 
to permanent discontinuation of the study drug 
were evaluated regardless of whether they were 
adjudicated as cardiovascular outcome events. Ad-
verse events resulting in discontinuation of the 
study drug occurred in 13.6% of the subjects in 
the sibutramine group and 12.4% of the subjects 
in the placebo group. The most common adverse 
event in both groups was myocardial infarction. 
Serious adverse events were reported in 42.1% of 
the subjects in the sibutramine group and 40.5% 
in the placebo group. Adverse events with an in-
cidence of at least 0.5% or with a significant be-
tween-group difference (for a summary, see the 
Supplementary Appendix) are those reported by 
investigators and do not necessarily reflect adju-
dicated primary outcome events. A review of seri-
ous adverse events showed that there were signifi-
cantly more reports of myocardial ischemia and 
ischemic stroke in subjects taking sibutramine 
than in subjects taking placebo and significantly 
more reports of second-degree atrioventricular 
block and acute pancreatitis in subjects taking 
placebo than in subjects taking sibutramine.
DISCUSSION
The SCOUT trial evaluated the long-term effects 
of sibutramine, as compared with placebo, on 
the incidence of cardiovascular disease and death 
among high-risk subjects who were participating 
in diet and exercise programs. Intentional modest 
weight loss has been shown to reduce the sever-
ity of obesity-related illness and associated car-
diovascular risk factors.16-18 To date, however, 
long-term weight management has not been 
shown to reduce morbidity or mortality except 
after bariatric surgery.19,20
In the SCOUT trial, event rates in the sibutra-
mine group were lower than expected, and the 
sibutramine group lost more weight than the 
placebo group and maintained the weight loss. 
However, the risk of a primary outcome event 
was increased by 16% in the sibutramine group 
as compared with the placebo group (P = 0.02). 
This increase was due to a higher incidence of 
nonfatal events (myocardial infarction and stroke), 
with no significant difference between the study 
groups in the incidence of cardiovascular death 
or death from any cause. An analysis of the three 
cardiovascular-risk groups showed that the risk M
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of nonfatal events was increased among sibutra-
mine-treated subjects who had preexisting car-
diovascular conditions (i.e., the CV-only and 
CV–DM groups) but was not evident in the DM-
only group, in which the subjects did not have a 
history of cardiovascular disease. An analysis of 
the effect of treatment did not show significant 
differences among the three risk groups.
Possible explanations for the excess of non-
fatal events in subjects receiving sibutramine in-
clude the recognized effect of increased blood 
pressure on cardiovascular outcomes21-25 and the 
combined peripheral and central sympathomi-
metic effects of sibutramine.26 Despite a decrease 
in mean blood pressure in both study groups 
during the lead-in period, the mean blood pres-
sure after the subjects underwent randomization 
remained consistently and significantly higher 
in the subjects taking sibutramine than in those 
taking placebo, although the mean difference was 
small (1 to 2 mm Hg). The mean pulse rate was 
also consistently higher in the sibutramine group 
than in the placebo group over the course of the 
treatment period, and an elevated resting pulse 
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Figure 3. Hazard Ratios in the Total Cohort and the Three Cardiovascular-Risk Groups.
Hazard ratios for the primary end point, individual components of the primary end point, and death from any cause (a secondary end 
point) are shown in the overall population and in the three cardiovascular-risk subgroups; hazard ratios for resuscitation after cardiac 
 arrest are shown for the overall population only, owing to the small number of events in the three cardiovascular-risk subgroups. The 
 diabetes mellitus (DM)–only group comprised subjects with a history of type 2 diabetes mellitus and with at least one other risk factor 
(i.e., hypertension controlled on medication, dyslipidemia, current cigarette smoking, or diabetic nephropathy with evidence of micro-
albuminuria) but no history of protocol-specified coronary artery disease, cerebrovascular disease, or peripheral arterial occlusive dis-
ease. The cardiovascular (CV)–only group comprised subjects who had a history of protocol-specified coronary artery disease, cerebro-
vascular disease, or peripheral arterial occlusive disease but did not have a history of type 2 diabetes mellitus with at least one other risk 
factor. The CV–DM group comprised subjects with a history of protocol-specified coronary artery disease, cerebrovascular disease, or 
peripheral arterial occlusive disease and a history of type 2 diabetes mellitus with at least one other risk factor. In the case of 60 patients 
(34 in the sibutramine group and 26 in the placebo group), there was insufficient information to classify them into one of the three 
cardiovascular-risk groups.
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rate is an independent predictor of cardiovascu-
lar risk.27-29 Elevated blood pressure or pulse rate 
has typically been associated with increases in 
both nonfatal and fatal events; a selective effect 
on nonfatal events has been observed previously.29
The weight loss that was achieved in both 
study groups during the lead-in period was large-
ly maintained over the course of the study (mean 
duration, 3.4 years). The long-term maintenance 
of reduced weight in placebo-treated subjects is 
unusual but may relate to the fact that our co-
hort was older than the cohorts in most obesity 
trials; it is known that weight tends to stabilize 
in subjects who are older than 60 years of age,30 
whereas younger subjects gain about 1 kg per 
year.31,32
During the 6-year study period in the SCOUT 
trial, the incidence of cardiovascular disease was 
reduced in most of Europe and Australia, and 
there were improvements in the medical man-
agement of cardiovascular disease.33-35 In addi-
tion, the optimal medical management of blood 
pressure, blood glucose levels, and lipid levels 
was repeatedly emphasized throughout the trial. 
The original expectation of an annual incidence 
rate of 7.0% in the placebo group was based on 
data that were available almost a decade ago, 
when the trial was initially designed. Despite the 
fact that we selectively recruited subjects with 
the highest cardiovascular risk (with the result 
that 60% of the subjects were in the CV–DM 
group) and extended the trial period, less than 
half the predicted primary outcome events oc-
curred. The decision not to extend the trial fur-
ther in order to accumulate more primary out-
come events was made because approximately 
40% of the subjects had discontinued treatment, 
and further discontinuations could have under-
mined the trial’s validity.
Our study has some limitations. First, because 
the overall event rate was lower than originally 
intended, the statistical power of the study, espe-
cially for potential subgroup analyses, was re-
duced. Second, for ethical and practical reasons, 
no true placebo group (i.e., a group that received 
no treatment at all) was included. Safety consid-
erations also required that all the subjects receive 
an initial 6-week course of treatment with sibu-
tramine in addition to advice on lifestyle modi-
fication in order to exclude from randomization 
subjects who had a sensitivity to sibutramine; 
thus, the weight changes that were seen in the 
placebo group after randomization may have re-
sulted from the initial effects of sibutramine 
rather than from diet and exercise alone. No data 
on background events in similar populations 
that did not receive active weight management or 
initial sibutramine treatment are available for 
comparison. Third, in order to achieve the primary 
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Figure 4. Kaplan–Meier Plots of the Incidence of a Primary Outcome Event 
and Death from Any Cause, According to the Time from Randomization.
Panel A shows the Kaplan–Meier results for the primary outcome, which 
included nonfatal myocardial infarction, nonfatal stroke, resuscitation after 
cardiac arrest, and cardiovascular death. The analyses were adjusted for 
age, sex (with male sex as the reference), and country. Panel B shows the 
results for death from any cause, which was a secondary outcome.
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objective of the SCOUT trial, high-risk subjects 
were selectively recruited; the vast majority did 
not meet the treatment criteria specified on the 
current sibutramine label. Only high-risk subjects 
who tolerated sibutramine during the 6-week 
lead-in period and met additional criteria for 
randomization were eligible for long-term treat-
ment in the study; the exclusion of the subjects 
at highest risk may have minimized differences 
in outcomes between the study groups. Fourth, 
the subjects in the SCOUT trial continued to 
receive therapy for up to 6 years, regardless of 
the weight loss they achieved, in order to mini-
mize the number of subjects who discontinued 
the study drug, and this could have altered the 
risk–benefit ratio of sibutramine. The discontinu-
ation rates of 40 and 42% in the sibutramine 
and placebo groups, respectively, although less 
than those predicted on the basis of previous 
obesity trials,36,37 exceeded the rates reported in 
trials of cardiovascular outcomes in nonobese 
subjects13 and may have led to some convergence 
of the two groups. Finally, the repeated reinforce-
ment of individualized cardioprotective diet and 
exercise programs and the observed maintenance 
of weight loss in both groups may also have lim-
ited the treatment differences. Despite these limi-
tations, the trial allowed us to assess the effect of 
intentional modest weight loss with sibutramine 
on the risks of cardiovascular events and death 
with the usual intention-to-treat approach among 
patients at high cardiovascular risk.
In conclusion, the SCOUT trial showed that 
among subjects who were receiving long-term 
treatment with sibutramine, those with preexist-
ing cardiovascular conditions had an increased 
risk of nonfatal myocardial infarction and non-
fatal stroke but not of cardiovascular death or 
death from any cause. On the basis of these re-
sults, sibutramine should continue to be excluded 
from use in patients with preexisting cardiovas-
cular disease.
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